Ad News Live
January 21, 2026
J&J 2026 Profit Forecast: Johnson & Johnson on Wednesday issued a 2026 financial outlook that topped analyst expectations.
The company said both revenue and profit are projected to exceed Wall Street forecasts.
The guidance includes a negative impact of several hundred million dollars.
The hit is linked to a recent U.S. drug pricing agreement reached earlier this month.
Executives said the outlook demonstrates resilience despite pricing concessions.
Johnson & Johnson is among 16 large pharmaceutical companies that agreed to reduce drug prices for U.S. consumers.
In exchange, the firms secured exemptions from tariffs introduced during the Trump administration.
Johnson & Johnson Chief Financial Officer Joseph Wolk said the company is unable to provide exact figures on the impact.
He said the cost amounts to several hundred million dollars.
Wolk noted that the company still expects to comfortably beat market expectations for 2026.
He said the results reflect strong execution across the business despite the added pressure.
Johnson & Johnson forecasts 2026 operational sales between $99.5 billion and $100.5 billion.
The outlook is higher than the $98.9 billion consensus estimate from analysts, according to LSEG data.
Johnson & Johnson projected full-year 2026 earnings of between $11.43 and $11.63 per share.
The guidance slightly tops the market consensus.
Analysts had been expecting a profit of about $11.45 per share.
The company also reported fourth-quarter earnings that came in above expectations.
Performance was driven by robust sales of its blood cancer drug Darzalex.
The psoriasis treatment Tremfya posted healthy growth.
The medical devices unit delivered steady results, providing additional support to overall profit.
Johnson & Johnson released its latest financial results a day after a court-appointed special master ruled that expert testimony connecting the company’s talc products to ovarian cancer could be presented in court.
The company has been defending lawsuits over its talc products in state and federal courts for years.
Johnson & Johnson continues to assert that its talc products are safe and do not cause cancer.
Johnson & Johnson delivered solid results even as it contends with ongoing challenges.
Tariff uncertainties are weighing on its medical devices division.
At the same time, its top-selling psoriasis drug, Stelara, faces mounting competition from biosimilars.
Stelara sales dropped more than analysts had predicted.
CFO Joseph Wolk emphasized the company’s strength, noting that growth continued despite the larger-than-expected decline in Stelara sales.
Johnson & Johnson emphasized robust growth in its portfolio excluding Stelara.
CFO Joseph Wolk said the company’s other products are growing at a rate of 14% to 15%.
He added that these products will be central to the company’s growth over the next few years and through the remainder of the decade.
The company posted adjusted quarterly earnings of $6 billion, or $2.46 per share.
This came slightly above analysts’ forecast of $2.44 per share.
Johnson & Johnson posted quarterly revenue of $24.56 billion, beating Wall Street’s estimate of $24.16 billion.
The company’s Innovative Medicine division, its biggest segment, recorded a 10% increase in sales to $15.76 billion.
Analysts had projected $15.37 billion.
Sales in the medical devices unit rose 7.5% to $8.8 billion, contributing to the company’s overall strong quarterly performance.
Image: AI‑generated illustration, created and published by AD News Live.
Follow Us
AD News Live
